IgG antibody

100% Secure

Rabbit F(ab')2 anti Mouse IgG:FITC

Product Type
Polyclonal Antibody
Polyclonal IgG
Product Code Applications Pack Size List Price Quantity
1 mg loader

FITC conjugated Rabbit F(ab')2 anti Mouse IgG antibody recognizes all subclasses of mouse IgG.

Some cross reactivity with mouse IgM and IgA is expected, as is cross reactivity with rat IgG. Cross reactivity with human serum proteins has been minimised by solid phase adsorption.

Product Details

Target Species
Species Cross-Reactivity
Target SpeciesCross Reactivity
N.B. Antibody reactivity and working conditions may vary between species.
Product Form
F(ab')2 fragment of IgG conjugated to Fluorescein Isothiocyanate Isomer I (FITC) - liquid
Antiserum Preparation
Antisera to Mouse IgG were raised by repeated immunisation of rabbits with highly purified antigen. Purified IgG was prepared from whole serum by affinity chromatography. F(ab')2 fragments were prepared by pepsin digestion of the IgG followed by a gel filtration step to remove the remaining intact IgG or Fc fragments.
Buffer Solution
Phosphate buffered saline
Preservative Stabilisers
0.09%Sodium Azide
Purified mouse IgG.
Approx. Protein Concentrations
F(ab')2 concentration 1.0 mg/ml

Storage Information

This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.
12 months from date of despatch

More Information

Entrez Gene
GO Terms
GO:0003823 antigen binding
GO:0002455 humoral immune response mediated by circulating immunoglobulin
GO:0019731 antibacterial humoral response
GO:0042571 immunoglobulin complex, circulating
GO:0005886 plasma membrane
GO:0016021 integral to membrane
GO:0005576 extracellular region
GO:0001788 antibody-dependent cellular cytotoxicity
GO:0001798 positive regulation of type IIa hypersensitivity
GO:0001812 positive regulation of type I hypersensitivity
GO:0006910 phagocytosis, recognition
GO:0006911 phagocytosis, engulfment
GO:0006958 complement activation, classical pathway
GO:0050766 positive regulation of phagocytosis
For research purposes only

Applications of IgG antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
Flow Cytometry 1/25 1/100
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Flow Cytometry
Use 50ul of the suggested working dilution to label 106 cells in 100ul.

Application Based External Images

Flow Cytometry


Product Specific References

References for IgG antibody

  1. O-charoenrat, P. et al. (2000) Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells.
    Cancer Res. 60 (4): 1121-8.
  2. Lamote, I. et al. (2004) Influence of 17beta-estradiol, progesterone, and dexamethasone on diapedesis and viability of bovine blood polymorphonuclear leukocytes.
    J Dairy Sci. 87 (10): 3340-9.
  3. Dalli, J. et al. (2008) Annexin 1 mediates the rapid anti-inflammatory effects of neutrophil-derived microparticles.
    Blood. 112 (6): 2512-9.
  4. Fleming, E.H. et al. (2006) Respiratory syncytial virus F envelope protein associates with lipid rafts without a requirement for other virus proteins.
    J Virol. 80: 12160-70.
  5. Peretti, M. et al. (2001) Expression of the three human major histocompatibility complex class II isotypes exhibits a differential dependence on the transcription factor RFXAP.
    Mol Cell Biol. 21: 5699-709.
  6. Krawczyk, M. et al. (2005) New functions of the major histocompatibility complex class II-specific transcription factor RFXANK revealed by a high-resolution mutagenesis study.
    Mol Cell Biol. 25: 8607-18.
  7. Frenzel, R. et al. (2006) The human thyrotropin receptor is predominantly internalized by beta-arrestin 2.
    Endocrinology. 147: 3114-22.
  8. Brancaleone, V. et al. (2011) Evidence for an anti-inflammatory loop centered on polymorphonuclear leukocyte formyl peptide receptor 2/lipoxin A4 receptor and operative in the inflamed microvasculature.
    J Immunol. 186: 4905-14.
  9. Waclavicek, M. et al. (2009) Analysis of the early response to TSST-1 reveals Vbeta-unrestricted extravasation, compartmentalization of the response, and unresponsiveness but not anergy to TSST-1.
    J Leukoc Biol. 85: 44-54.
  10. Maderna, P. et al. (2010) FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis.
    FASEB J. 24: 4240-9.
  11. Ioannou, N. et al. (2011) Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells.
    Br J Cancer. 105: 1554-62.
  12. Renshaw, D. et al. (2010) Downstream gene activation of the receptor ALX by the agonist annexin A1.
    PLoS One. 5. pii: e12771.
  13. Bena, S. et al. (2012) Annexin A1 interaction with the FPR2/ALX receptor: identification of distinct domains and downstream associated signaling.
    J Biol Chem. 287: 24690-7.
  14. Mehta, K. et al. (2016) Characterization of hepcidin response to holotransferrin in novel recombinant TfR1 HepG2 cells
    Blood Cells Mol Dis. Jun 30 [Epub ahead of print]
  15. Puvanenthiran, S. et al. (2016) Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.
    Int J Oncol. 49 (5): 1825-38.
  16. Ioannou, N. et al. (2013) Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells.
    BMC Cancer. 13: 41.
  17. Khan, T. et al. (2020) Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer
    Oncology Reports. 44 (6): 2581-94.
  18. Reitsma, L.M. et al. (2020) Effects of oral calcium bolus supplementation on intracellular polymorphonuclear leukocyte calcium levels and functionality in primiparous and multiparous dairy cows.
    J Dairy Sci. 103 (12): 11876-88.
  19. Nadkarni, S. et al. (2019) Identification of an activated neutrophil phenotype in polymyalgia rheumatica during steroid treatment: a potential involvement of immune cell cross-talk.
    Clin Sci (Lond). 133 (7): 839-851.

Fluorescent Spectraviewer

Watch the Tool Tutorial Video ▸

How to Use the Spectraviewer

Watch the Tool Tutorial Video ▸
  • Start by selecting the application you are interested in, with the option to select an instrument from the drop down menu or create a customized instrument
  • Select the fluorophores or fluorescent proteins you want to include in your panel to check compatibility
  • Select the lasers and filters you wish to include
  • Select combined or multi-laser view to visualize the spectra